1,167 reports of this reaction
1.0% of all DEXLANSOPRAZOLE reports
#19 most reported adverse reaction
REBOUND ACID HYPERSECRETION is the #19 most commonly reported adverse reaction for DEXLANSOPRAZOLE, manufactured by Takeda Pharmaceuticals America, Inc.. There are 1,167 FDA adverse event reports linking DEXLANSOPRAZOLE to REBOUND ACID HYPERSECRETION. This represents approximately 1.0% of all 112,812 adverse event reports for this drug.
Patients taking DEXLANSOPRAZOLE who experience rebound acid hypersecretion should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
REBOUND ACID HYPERSECRETION is a less commonly reported adverse event for DEXLANSOPRAZOLE, but still significant enough to appear in the safety profile.
In addition to rebound acid hypersecretion, the following adverse reactions have been reported for DEXLANSOPRAZOLE:
The following drugs have also been linked to rebound acid hypersecretion in FDA adverse event reports:
REBOUND ACID HYPERSECRETION has been reported as an adverse event in 1,167 FDA reports for DEXLANSOPRAZOLE. This does not prove causation, but indicates an association observed in post-market surveillance data.
REBOUND ACID HYPERSECRETION accounts for approximately 1.0% of all adverse event reports for DEXLANSOPRAZOLE, making it a notable side effect.
If you experience rebound acid hypersecretion while taking DEXLANSOPRAZOLE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.